Authors
Mutasem Elfalah, Enrico Borelli, Paola Marolo, Michele Reibaldi, Vincenco De Angelis, Carlo De Rosa, Francesco Iatì, Niccolò Castellino, Sandrine Anne Zweifel, Yacoub A Yousef, Daniela Bacherini, Andrea Lucisano, Adriano Carnevali, Robert Rejdak, Giuseppe Giannaccare, Vincenzo Scorcia, Mario Damiano Toro
Published in
Eye (London, England). Jul 24, 2026. Epub Jul 24, 2026.
Abstract
There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with intermediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD).
This retrospective multicentre study evaluated the functional and morphological outcomes of TSLI in patients with stage 2 and stage 3 iAMD with RPD. Autofluorescence (AF), Optical Coherence Tomography (OCT), Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), Macular Sensitivity (MS) and adverse events, were recorded at baseline, 1 month and 3 months follow-up after treatment.
Thirty eyes from 30 patients, (15 ♂: 15 ♀), mean age (70.3 ± 7.8 years) were included. BCVA improved significantly, from mean baseline 65.6 ± 8.6 ETDRS letters to 66.9 ± 8.0 at 1 month and 69.1 ± 7.8 at 3 months (ANOVA, p < 0.0001, respectively), along with MS, (ANOVA p < 0.001). There was a significant increase of stage 1 RPD (p = 0.002) and a decrease in stage 3 RPD (p = 0.020). The Outer Nuclear Layer (ONL) thickness increased significantly (ANOVA, p < 0.0001). No adverse events were recorded.
TSLI appears to be an effective, safe technique in patients with iAMD and RPD, leading to structural and functional improvements in short-term follow-up.
PMID:
42498777
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0